Cor­rect­ed: Mer­ck KGaA’s mixed Phase 2 lu­pus re­sults; Zymeworks paus­es work on ADC

Plus, news about Tris Phar­ma and ARS Phar­ma­ceu­ti­cals:

Mer­ck KGaA’s lu­pus drug yields mixed da­ta in mid-stage tri­al: The drug­mak­er’s TLR7/8 in­hibitor, called en­pa­toran …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER